Emerging cardiac CT biomarkers: a systematic review of diagnostic and prognostic utility in cardiovascular disease
Exploration of Cardiology · 2025
DOI: 10.37349/ec.2025.101278 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Exploration of Cardiology, 2025. Verfasst von Mubariz Ahmed Hassan und 9 weiteren Autor:innen. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Cardiac computed tomography (CT) has evolved from an anatomic test to a platform that quantifies functional, inflammatory, and tissue-characterization biomarkers. We synthesized evidence on the diagnostic and prognostic value of CT-based biomarkers.
Methods
Systematic review of 29 human studies (2015–2025) appraising low-attenuation plaque (LAP), perivascular fat attenuation index (FAI/PCAT), total/non-calcified plaque burden, epicardial adipose tissue, CT-derived fractional flow reserve (FFR-CT), and CT myocardial perfusion. Study quality was assessed with risk of bias (RoB) 2.0, Newcastle-Ottawa Scale (NOS), and AMSTAR 2.
Results
CT biomarkers extended risk assessment beyond stenosis severity. LAP burden > 4% predicted myocardial infarction (MI) [hazard ratio (HR) 4.65; 95% CI 2.06–10.5] and per-doubling LAP predicted MI (HR 1.60; 95% CI 1.10–2.34). Perivascular FAI/PCAT showed independent prognostic value: high FAI was associated with ~2-fold higher cardiac mortality (derivation HR 2.15, validation HR 2.06), and RCA PCAT ≥ −70.5 Hounsfield unit (HU) predicted MI (HR 2.45) with additive risk when combined with high-risk plaque (HRP) features (reported up to ~6-fold vs. reference). FFR-CT achieved up to 81% diagnostic accuracy (sensitivity ~86%, specificity ~79%) vs. invasive FFR, improving specificity over CTA alone. Emerging metrics (e.g., total plaque volume, CT perfusion) demonstrated incremental discrimination in selected cohorts, though standardization remains variable.
Discussion
CT-based biomarkers provide measurable diagnostic and prognostic information on coronary anatomy, function, inflammation, and tissue health. Priorities include standardized acquisition/analysis, multicenter validation, and integration into decision pathways to optimize individualized risk stratification and therapy.
Zitieren
APA
Hassan, M. A., Mhanna, M., Alzahrani, A., Afzal, M. A., Abdelkarim, O., Bello, R., Savoia, P., Suksaranjit, P., Lima, J. A. C., & Delcour, K. (2025). Emerging cardiac CT biomarkers: a systematic review of diagnostic and prognostic utility in cardiovascular disease. Exploration of Cardiology. https://doi.org/10.37349/ec.2025.101278
Vancouver
Hassan MA, Mhanna M, Alzahrani A, Afzal MA, Abdelkarim O, Bello R, et al. Emerging cardiac CT biomarkers: a systematic review of diagnostic and prognostic utility in cardiovascular disease. Exploration of Cardiology. 2025. doi:10.37349/ec.2025.101278
BibTeX
@article{Hassan2025,
author = {Hassan, Mubariz Ahmed and Mhanna, Mohammed and Alzahrani, Ashraf and Afzal, Muhammad Adil and Abdelkarim, Ola and Bello, Rodrigo and Savoia, Paulo and Suksaranjit, Promporn and Lima, Joao A. C. and Delcour, Kimberly},
title = {Emerging cardiac CT biomarkers: a systematic review of diagnostic and prognostic utility in cardiovascular disease},
journal = {Exploration of Cardiology},
year = {2025},
doi = {10.37349/ec.2025.101278}
}
EUVIMED